Navigation Links
QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
Date:9/24/2008

Separate survey shows high prevalence of "bothersome" vaginal atrophy symptoms among sexually active and non-sexually active postmenopausal women; results presented today at 19th Annual North American Menopause

Society Meeting

ANN ARBOR, Mich., Sept. 24 /PRNewswire/ -- Additional results of a Phase 3 study for Ophena(TM) (ospemifene tablets) for the treatment of symptoms of vulvovaginal atrophy (VVA) in postmenopausal women showed that Ophena(TM) significantly improves a broad range of clinical signs of vulvovaginal atrophy, including petechiae, pallor, friability, vaginal dryness and redness in mucosa. These are all visual observations of VVA assessed during gynecological examination and were pre-defined secondary endpoints in the study. Results were announced today by QuatRx Pharmaceuticals in a poster presentation at the 19th Annual North American Menopause Society meeting in Orlando, Florida.

Vulvovaginal atrophy is a common and progressive condition associated with menopause. Earlier this year, QuatRx announced a Phase 3 study for Ophena(TM) met all four of its co-primary endpoints. The results of the study showed statistically significant improvements in vaginal dryness and dyspareunia (painful intercourse), two of the most bothersome symptoms associated with VVA. The study also demonstrated favorable effects of Ophena(TM) on vaginal wall health as compared to placebo, measured as changes in the proportion of parabasal and superficial cells in the vaginal epithelium, as well as a favorable effect on vaginal pH levels.

The multi-center, double-blind, placebo-controlled study was conducted at 80 U.S. centers and involved 826 postmenopausal women. The additional results announced today showed that after 12 weeks of treatment, the mean scores for common clinical signs of vaginal atrophy were decreased by a statistically significant margin in the Ophena(TM) groups when compared with placebo. These pos
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
2. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
3. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
4. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
5. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
9. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
10. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
11. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... , April 24, 2015  Elekta has CE ... Monaco® treatment planning system , enabling European clinics to ... major treatment techniques including advanced 3D planning, IMRT, VMAT ... Monaco ® ... well improved workflow efficiency. Advancements in 3D planning as ...
(Date:4/23/2015)... Calif., April 23, 2015  Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, today reported net income ... or $1.12 per diluted share.  Net income for the ... $0.56 per diluted share, and non-GAAP net income was ... Net sales for the quarter ended March 31, 2015 increased ...
(Date:4/23/2015)... - Health Canada is working with the Canadian manufacturers ... information regarding the risk of serious cardiovascular side effects ... used at high doses (at or above 2400 mg/day). ... Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) ... inflammation. The majority of ibuprofen products in ...
Breaking Medicine Technology:Elekta CE marks for Monaco v5.10 treatment planning system 2Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4
... Corporation ("Futuremed") (TSX: FMD) and Cardinal Health Canada Inc. ... Inc. (NYSE: CAH ), announced today that ... morning regarding Cardinal Health Canada,s proposed acquisition of all ... for CAD $8.15 per Common Share in cash (the ...
... WORTH, Texas, February 16, 2012 Medical ... in Fort Worth, Texas on March 14-15, 2012. In ... and MD&M East (Philadelphia, PA), MD&M Texas Conference is ... device design and development presented by experienced medtech industry ...
Cached Medicine Technology:Cardinal Health Canada Inc. Receives Competition Bureau Clearance for Acquisition of Futuremed 2Cardinal Health Canada Inc. Receives Competition Bureau Clearance for Acquisition of Futuremed 3Cardinal Health Canada Inc. Receives Competition Bureau Clearance for Acquisition of Futuremed 4Medical Design & Manufacturing Conference to be Launched in Texas in March 2012 2
(Date:4/25/2015)... (PRWEB) April 25, 2015 Parker and Sons ... and cooling, has spiked in Arizona alongside the growing economy. ... additional forty employees for April to help account for the ... forty employees in April is something we are enthusiastic about. ... said Paul Kelly, president at Parker and Sons. , Indeed, ...
(Date:4/25/2015)... 25, 2015 On Friday, April 17, ... Journal’s annual Best Implementation Award. This award is ... best use of RFID technology to improve its manufacturing, ... company that best demonstrates how RFID is delivering real ... RFID Journal Live! 2015 in San Diego, the RFID ...
(Date:4/24/2015)... York, NY (PRWEB) April 24, 2015 ... sober living residence in Westchester County. Just 35 miles ... help transition individuals back into everyday life while recovering ... Thursday, May 7, 2015, will allow therapists, doctors and ... areas and learn more about the opportunities offered by ...
(Date:4/24/2015)... California (PRWEB) April 24, 2015 Ryadon ... a wide range of capabilities and services to complement ... , Ryadon's Quantity Discount Program will be offered on ... follows: , Order 4-19: Receive 10% discount - Order ... by Using the Drawer Slides Products, ...
(Date:4/24/2015)... York (PRWEB) April 24, 2015 ... move forward in the federal multidistrict litigation underway ... According to court documents, the parties involved in ... April 16th detailing, among other things, preparation for ... that counsel for both plaintiffs and defendants have ...
Breaking Medicine News(10 mins):Health News:Parker and Sons Plans to Expand in 2015 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... have an occasional "bad day" are at increased risk of ... ,It is not uncommon for people over age 70 to ... least half a day and/or cutting back on usual activities ... this is just a normal sign of aging and not ...
... women with endometriosis may one day lead to new ... new research suggests. What's more, the researchers may have ... unfortunate consequence of the condition. ,Anywhere from 10 to ... occurs when the tissue //that lines the uterus, the ...
... biopsy will tell you it’s not a pleasant experience. Now ... for prostate cancer and eliminate the need for unnecessary biopsies ... his prostate after blood tests revealed elevated levels of PSA ... prostate cancer. "Every time they take a section through the ...
... The first major conference on the deadly SARS epidemic ... today. More than 1,000 scientists and clinicians gathered to ... scientific findings and talk about control strategies for a ... infected 8,460. ,The meeting in Kuala Lumpur will also ...
... including non-smokers, are misusing nicotine patches and gum. The authors ... up for health trouble if they smoke and use the ... use the products to maintain their nicotine levels. ,But an ... have lied on the survey. And even if they weren't, ...
... study shows young children with high cholesterol levels are ... and adulthood. Researchers studied the eating habits and cholesterol ... years. The children were examined by doctors and had ... cholesterol, measured periodically. ,Results of the study show children ...
Cached Medicine News:Health News:Teens Misusing Nicotine-Replacement Products 2
... and value!, Comfortable feel and ... contoured handle , Finer control while ... action , Completely autoclavable for easy ... for recalibration , Easy-to-read precision micrometer ...
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... 2000 Pipette is a synonym for pipetting ... robust design, and superior operating comfort. Its ... the measuring stroke and blow-out as well ... system ensures utmost accuracy and precision. Ejection ...
... Hamilton is precision, ergonomics, and value!, ... fatigue with soft non-slip, contoured handle ... smooth, light plunger spring action , ... sterilization without the need for recalibration ...
Medicine Products: